company background image
JAGX logo

Jaguar Health NasdaqCM:JAGX Stock Report

Last Price

US$0.98

Market Cap

US$9.1m

7D

2.6%

1Y

-95.6%

Updated

22 Nov, 2024

Data

Company Financials +

JAGX Stock Overview

A commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. More details

JAGX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Jaguar Health, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jaguar Health
Historical stock prices
Current Share PriceUS$0.98
52 Week HighUS$24.30
52 Week LowUS$0.90
Beta0.88
11 Month Change-13.62%
3 Month Change-15.84%
1 Year Change-95.61%
33 Year Change-99.98%
5 Year Change-99.99%
Change since IPO-100.00%

Recent News & Updates

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Recent updates

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Jan 22
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jun 10
Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jan 23
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment

Oct 17

Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront

Aug 25

Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule

Aug 19

Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea

Aug 09

Jaguar stock rises on license deal with SynWorld for Canalevia in China

Jun 29

Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory

Mar 07

Jaguar Health shares jumps 13% after pricing $15M direct offering

Jan 13

Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients

Jan 11

Jaguar Health leaps higher in new year

Jan 05

Jaguar Health inks second Mytesi royalties agreement for $6M

Dec 23

Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Dec 02
Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%

Nov 30

Jaguar Health EPS misses by $0.10, misses on revenue

Nov 16

Jaguar Health receives positive Nasdaq listing determination

Oct 29

Shareholder Returns

JAGXUS PharmaceuticalsUS Market
7D2.6%-3.8%-1.0%
1Y-95.6%9.8%30.3%

Return vs Industry: JAGX underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.

Return vs Market: JAGX underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is JAGX's price volatile compared to industry and market?
JAGX volatility
JAGX Average Weekly Movement10.2%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: JAGX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: JAGX's weekly volatility has decreased from 24% to 10% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a49Lisa Contejaguar.health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.

Jaguar Health, Inc. Fundamentals Summary

How do Jaguar Health's earnings and revenue compare to its market cap?
JAGX fundamental statistics
Market capUS$9.10m
Earnings (TTM)-US$37.74m
Revenue (TTM)US$10.48m

0.9x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JAGX income statement (TTM)
RevenueUS$10.48m
Cost of RevenueUS$2.09m
Gross ProfitUS$8.40m
Other ExpensesUS$46.14m
Earnings-US$37.74m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.08
Gross Margin80.11%
Net Profit Margin-360.13%
Debt/Equity Ratio212.7%

How did JAGX perform over the long term?

See historical performance and comparison